Welcome to our dedicated page for Elicio Therapeutics SEC filings (Ticker: ELTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elicio Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company focused on cancer immunotherapies. Its disclosures cover common stock registered on The Nasdaq Capital Market, emerging growth company reporting status, operating and financial results, corporate updates, and material-event reports.
Recent filings also address capital-structure matters, including an at-the-market equity program tied to a Form S-3 registration statement, as well as Regulation FD and other event disclosures for ELI-002, AMPLIFY-7P, AMPLIFY-201, mKRAS-specific T cell response data, scientific publications, governance matters, shareholder voting topics, and risk-related clinical and regulatory updates.
Elicio Therapeutics, Inc. files its annual report describing a clinical-stage oncology pipeline built on its lymph node–targeting Amphiphile (AMP) immunotherapy platform. The lead candidate, ELI-002 7P, targets seven common KRAS mutations in pancreatic and other solid tumors and is in a randomized Phase 2 PDAC trial.
Phase 1 data for ELI-002 2P and 7P showed high KRAS-specific T cell response rates, tumor biomarker declines, and encouraging relapse-free and overall survival signals. Elicio is also advancing preclinical AMP vaccines ELI-007 for BRAF-driven cancers and ELI-008 for TP53-mutant tumors, supported in part by research grants and an exclusive AMP license from MIT.
Elicio Therapeutics reported 2025 results and highlighted progress for its lead KRAS-targeted cancer immunotherapy ELI-002 7P. R&D expense fell to $24.9 million from $33.7 million in 2024 as its Phase 2 AMPLIFY-7P trial moved more patients into observation, while G&A rose to $12.8 million from $11.3 million. Net loss narrowed to $39.5 million, or $2.58 per share, from $51.9 million, or $4.25 per share. Cash and cash equivalents were $18.6 million as of December 31, 2025, up from $17.6 million a year earlier, helped by at-the-market equity proceeds of about $4.9 million in Q4 2025 and $6.3 million in Q1 2026 to date.
The company reiterated that its cash plus expected at-the-market proceeds are projected to fund operations into Q3 2026, beyond the anticipated event-driven primary disease-free survival analysis for the Phase 2 AMPLIFY-7P trial in the first half of 2026. Elicio reported fewer disease progressions and deaths than projected to date in this randomized study and plans to seek an End-of-Phase 2 meeting with the FDA, finalize a Phase 3 protocol, and advance ELI-002 7P toward a registrational trial in resected mKRAS pancreatic cancer, while exploring expansion into neoadjuvant, metastatic PDAC and other mKRAS-positive tumors.
Elicio Therapeutics, Inc. filed Pre-Effective Amendment No. 1 to its registration statement (S-3/A) to delay the registration statement’s effective date by including the cover-page delaying amendment language.
The amendment states it does not modify the prospectus, includes an expenses table showing a SEC registration fee of $55,240.00 and a FINRA filing fee of $60,500.00, and describes indemnification provisions under Delaware law, the company’s charter and bylaws, director and officer indemnification agreements, a six-year indemnity/anti-amendment covenant tied to a Merger Agreement, and a six-year prepaid tail D&O policy.
Elicio Therapeutics, Inc. filed a shelf registration to offer up to $400,000,000 of securities, including common stock, preferred stock, debt securities, warrants and units, to be sold from time to time February 27, 2026.
The prospectus describes that specific terms, pricing and offering methods will be set forth in future prospectus supplements; the company noted its common stock trades on Nasdaq at $11.74 per share as of February 26, 2026.
Elicio Therapeutics CEO Robert Connelly received new equity awards in the form of restricted stock units and stock options. On February 2, 2026, he was granted 73,600 restricted stock units of common stock at a price of $0, increasing his directly held common shares to 120,570.
He was also granted 147,200 stock options with an exercise price of $8.10 per share, all held directly. Both the RSUs and options vest 25% on February 2, 2027, with the remaining portions vesting over the following three years, contingent on his continued service to the company.
Elicio Therapeutics granted equity awards to its Chief Strategy and Financial Officer, Preetam Shah, on February 2, 2026. He received 24,000 restricted stock units, each representing one share of common stock at no cost on grant, and 47,900 stock options to buy common shares at an exercise price of $8.10 per share.
The RSUs vest 25% on February 2, 2027, with the rest vesting in annual installments over the following three years, contingent on continued service. The options vest 25% on February 2, 2027, with the remainder vesting in monthly installments over three years thereafter, also subject to continued service.
Elicio Therapeutics granted equity awards to its Chief Scientific Officer, Peter DeMuth. He received 20,800 restricted stock units at a price of $0 and now beneficially owns 21,543 common shares directly. The RSUs vest 25% on February 2, 2027, then annually over three more years, conditioned on continued service.
DeMuth also received a stock option for 41,600 shares of common stock with an exercise price of $8.10 per share. The option vests 25% on February 2, 2027, with the remaining portion vesting monthly over three years, also subject to his continued service.
Elicio Therapeutics, Inc. granted equity awards to executive Christopher Haqq, Executive Vice President, Head of R&D and Chief Medical Officer. On February 2, 2026, he received 25,400 restricted stock units (RSUs) of common stock at $0 cost and a stock option for 50,900 shares with an exercise price of $8.1 per share.
The 25,400 RSUs vest 25% on February 2, 2027, then annually over three additional years, contingent on continued service. The 50,900 options vest 25% on February 2, 2027, with the remainder vesting monthly over the following three years. After these grants, he directly holds 57,381 common shares and 50,900 options.
Elicio Therapeutics (ELTX) filed a resale registration covering up to 103,225 shares of common stock, issuable upon exercise of a warrant issued on June 3, 2025 to GKCC, LLC. The company will not receive proceeds from any sales by the selling stockholder; it may receive cash proceeds only if the warrant is exercised. The warrant is immediately exercisable, expires five years from issuance, and has a $7.75 per share exercise price, subject to a 49.99% beneficial ownership cap.
The selling stockholder may sell shares from time to time through public or private transactions at market or negotiated prices, using methods listed in the plan of distribution, including short sales after the registration statement is declared effective. ELTX trades on Nasdaq; the last reported sale price was $9.19 on November 12, 2025. As context, shares outstanding were 17,413,843 as of October 31, 2025; this is a baseline figure, not the amount being offered.
Elicio Therapeutics (ELTX) reported Q3 2025 results with a net loss of $10.1 million and total operating expenses of $8.0 million, down from $10.3 million a year ago. Year to date, net loss was $31.9 million.
Cash and cash equivalents were $20.6 million as of September 30, 2025. Management disclosed that these resources and expected needs raise substantial doubt about the company’s ability to continue as a going concern. Stockholders’ equity improved to $3.8 million from a $(11.3) million deficit at year-end 2024, reflecting capital actions.
During 2025, Elicio converted a $20.0 million senior secured convertible note (plus $0.3 million interest) into 3,500,573 shares in March, raised $9.2 million net in a January registered direct offering with accompanying warrants, generated $11.4 million net via ATM sales, and issued a $10.0 million senior secured promissory note in June with a warrant. Shares outstanding were 17,489,516 as of November 10, 2025.